In a regulatory filing, Rapport Therapeutics (RAPP) disclosed that its director Steven Paul bought 41.7K shares of common stock on September 12th in a total transaction size of $1.03M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP: